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Abstract
Introduction Chemokines and their receptors control immune
cell migration during infections as well as in autoimmune
responses. A 32 bp deletion in the gene of the chemokine
receptor CCR5 confers protection against HIV infection, but
has also been reported to decrease susceptibility to rheumatoid
arthritis (RA). The influence of this deletion variant on the clinical
course of this autoimmune disease was investigated.
Methods Genotyping for CCR5d32 was performed by PCR
and subsequent electrophoretic fragment length determination.
For the clinical analysis, the following extra-articular
manifestations of RA were documented by the rheumatologist
following the patient: presence of rheumatoid nodules, major
organ vasculitis, pulmonary fibrosis, serositis or a Raynaud's
syndrome. All documented CRP levels were analyzed
retrospectively, and the last available hand and feet radiographs
were analyzed with regards to the presence or absence of
erosive disease.
Results Analysis of the CCR5 polymorphism in 503 RA patients
and in 459 age-matched healthy controls revealed a significantly
decreased disease susceptibility for carriers of the CCR5d32
deletion (Odds ratio 0.67, P = 0.0437). Within the RA patient
cohort, CCR5d32 was significantly less frequent in patients
with extra-articular manifestations compared with those with
limited, articular disease (13.2% versus 22.8%, P = 0.0374). In
addition, the deletion was associated with significantly lower
average CRP levels over time (median 8.85 vs. median 14.1, P
= 0.0041) and had a protective effect against the development
of erosive disease (OR = 0.40, P  = 0.0047). Intriguingly,
homozygosity for the RA associated DNASE2 -1066 G allele
had an additive effect on the disease susceptibility conferred by
the wt allele of CCR5 (OR = 2.24, P = 0.0051 for carrier of both
RA associated alleles)
Conclusions The presence of CCR5d32 significantly
influenced disease susceptibility to and clinical course of RA in
a German study population. The protective effect of this
deletion, which has been described to lead to a decreased
receptor expression in heterozygous patients, underlines the
importance of chemokines in the pathogenesis of RA.
Introduction
Chemokines are chemoattractant cytokines, which play a cen-
tral role in T cell migration to and infiltration into the synovitic
lesions in joints of patients with rheumatoid arthritis (RA). The
CC chemokines RANTES, MIP-1α, MIP-1β, and MCP-1 are
strongly expressed in the synovial membrane of patients with
RA, and the primary CC chemokine receptor found on T cells
in rheumatoid synovium is CCR5 [1]. In addition, CCR5 is
expressed on tissue macrophages and on a high proportion of
T cells and natural killer (NK) cells in synovial fluid, while only
a small subpopulation of peripheral blood monocytes is CCR5
positive [2].
ANA: antinuclear antibodies; CCP: anti-cyclic citrullinated peptide; CI: confidence interval; CRP: C-reactive protein; PCR: polymerase chain reaction; 
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A 32 bp deletion in the CCR5 gene, termed CCR5d32,
results in a frame shift and a nonfunctional receptor, and
homozygosity for CCR5d32 has been shown to prevent trans-
mission of HIV-1, while heterozygosity prolongs the time
period between infection and the development of AIDS [3,4].
This deletion has also been found to be protective against the
development of RA [5-7], although the results remain some-
what controversial [8]. The gene copy number of chemokine-
ligand-3 like-1 (CCL3L1), a ligand for CCR5, has also been
found to be associated with susceptibility to RA [9].
In association studies with other autoimmune diseases, a sig-
nificant protective effect of the deletion against more severe
clinical courses of multiple sclerosis [10], systemic lupus ery-
thematodes [11], Crohn's disease [12], primary Sjögren's dis-
ease [13], Behçet's disease [14], and lung disease in
sarcoidosis [15] was observed. More recently, associations
with CCR5d32 have also been described for primary scleros-
ing cholangitis [16], cardiovascular disease [17], and juvenile
idiopathic arthritis [18].
In addition to its impact on disease susceptibility, the
CCR5d32 deletion has been shown to influence the clinical
course of RA. Patients carrying the CCR5d32 deletion were
found to be more frequently negative for rheumatoid factor
(RF) IgM and to have fewer swollen joints and a shorter period
of morning stiffness [19] and more frequently have a non-
severe course of RA [20], but results remain conflicting [6].
The goal of our study was, therefore, to investigate the influ-
ence of the CCR5d32 deletion on disease susceptibility and
on the clinical course of RA in a large and clinically well char-
acterized German patient cohort, which has previously been
analyzed for other genetic influences [21-23].
Materials and methods
Patients and controls
Five hundred and three patients with RA according to the
1987 revised criteria of the American College of Rheumatol-
ogy were included in the study. The study design was
approved by the University of Leipzig's ethics committee, and
informed consent was obtained from each patient before
study enrolment. Characteristics of the patient cohort are dis-
played in Table 1.
The presence of erosive joint disease was evaluated by analyz-
ing the previously available hand and feet radiographs of the
patients. The presence of extra-articular manifestations of the
disease was judged by retrospective chart review and by anal-
ysis of an available clinical database as described previously
[24]. The following extra-articular manifestations of the dis-
ease were documented by the rheumatologist following the
patient: presence of rheumatoid nodules, major organ vasculi-
tis, pulmonary fibrosis, serositis, or a Raynaud's syndrome.
Also by retrospective chart review, all available C-reactive pro-
tein (CRP) values from 359 patients were entered into a data
base, and the median value was calculated and used for sta-
tistical analysis.
RA cases from two separate studies were enrolled for the rep-
lication study. One-hundred and eight-two patients had been
part of a clinical study evaluating the influence of genetic
parameters on the progression of joint destruction [21,25] and
291 cases from an inception cohort of early RA patients were
enrolled, which has also been published previously
[21,26,27]. For both cohorts, radiographic data from hand and
feet radiographs were available, which had been scored
according to the Ratingen score [28]. Radiographs in the early
RA cohort were taken at study entry and subsequently after
two years of observation. In the retrospective study, the last
available radiograph taken during the first 10 years of disease
duration was analyzed (n = 158). In addition, in 118 patients,
a radiograph taken after more than 10 years of disease dura-
tion was available and was analyzed separately.
In addition, the CRP level at onset of disease as determined at
initial presentation with a rheumatologist was available for
analysis for the inception cohort of patients with early RA. Data
on extra-articular manifestations were not available in both
cohorts.
From among healthy blood donors with ethics committee
approval 459 age-matched control subjects with no history of
inflammatory arthritis were recruited. Controls and RA patients
Table 1
Characteristics of the rheumatoid arthritis patient cohort
Number of patients (female/male) 503 (369/134)
Age at onset (years) (median (range)) 49 (18 to 84)
Disease duration (years) (median (range)) 16 (2 to 70)
Patients positive for RF IgM (%) 76.9
Patients positive for RF IgA (%) 53.2
Patients positive for anti-CCP antibodies (%) 70.5
Patients positive for ANA (%) 36.9
Extra-articular manifestations
Rheumatoid nodules (%) 31.4
Polyserositis (%) 2.4
Interstitial pulmonary fibrosis (%) 5.5
Raynaud's syndrome (%) 5.2
Vasculitis (%) 12.5
Erosive disease (%) 80.7
ANA = Antinuclear antibodies; CCP = cyclic citrullinated peptide; 
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were Caucasian subjects of German origin with no discerna-
ble ethnic variation.
Genotyping methods
Genomic DNA was isolated from 10 ml of peripheral blood
using standard procedures and amplified by PCR. The follow-
ing oligonucleotide primers were used to detect CCR5 d32:
sense 5'-TTT ACC AGA TCT CAA AAA GAA G and anti-
sense 5'-GGA GAA GGA CAA TGT TGT AGG [2]. Reaction
mixtures (25 μl) contained DNA (100 to 200 ng) and oligonu-
cleotide primers (20 pM).
The mixture was heated at 94°C for three minutes and then
subjected to 40 amplification cycles of 94°C for 30 seconds,
62°C for one minute and 72°C for one minute, followed by a
final elongation cycle of 72°C for five minutes. The resulting
PCR products, 274 bp for CCR5 wildtype and 242 bp for
CCR5 d32, were separated on an ethidium bromide stained
2% agarose gel by electrophoresis and visualized by ultravio-
let light.
Detection of autoantibodies
The presence of RF was determined by laser nephelometry
according to the manufactor's instructions (Dade Behring, Lie-
derbach, Germany). Individuals with values of 40 IU/ml on at
least one occasion were counted as RF positive.
For the detection of anti-cyclic citrullinated peptide (CCP)
antibodies in patient sera, a commercially available, second
generation anti-CCP ELISA (Immunscan RA2, Generic
Assays, Dahlewitz, Germany) was used. A cut off of 25 U/ml
was used as a stringent criterion for anti-CCP antibody posi-
tivity.
Antinuclear antibodies (ANA) were detected using immunoflu-
oresence and a cut-off titer of 1:320 was used as a stringent
criterion for ANA positivity.
Statistical analysis
Allele and genotype frequencies of CCR5 d32 were obtained
by direct counting. For allele and genotyping comparisons, the
chi-squared test with 2 × 2 contigency tables (alleles) or 2 ×
3 contigency tables (genotypes) was used. Odds ratios (OR)
and 95% confidence intervals (CI) were calculated according
to Woolf's method. For the analysis of an interaction between
DNASE2 SNP alleles and CCR5d32 in conferring disease
susceptibility to RA, McNemar's test was used. P values of
less than 0.05 were considered statistically significant. The
software used was the Sigmastat program (Systat 2004, Rich-
mond, CA, USA).
Results
The distribution of genotypes and the observed allele frequen-
cies of the CCR5d32 deletion in healthy controls and RA
patients are shown in Table 2. The CCR5 dd32 deletion was
present less frequently in RA patients compared with controls
(allele frequency 10.0% versus 13.4%, P = 0.0262). Accord-
ingly, the wild type allele at CCR5 d32 conferred an OR of
1.39 (95% CI = 1.05 to 1.84) for developing RA.
Genotype analysis revealed the heterozygous presence of
CCR5d32 in 23.7% of the healthy controls and 17.3% of the
RA patients, while a homozygous CCR5d32 deletion was
present in 1.5% of the controls and 1.4% of the RA patients.
The distribution of genotypes complied with the Hardy-Wein-
berg equilibrium, and the differences resulted in a significantly
decreased disease susceptibility associated with the pres-
ence of the CCR5d32 deletion (OR = 0.67, P = 0.0437).
Stratification of RA patients and controls for gender showed
an equal distribution of the CCRd32 deletion in both sexes
(data not shown). No significant differences in the median age
at disease onset (median 49.5 years versus median 49.0
years) or the median disease duration at the time of analysis
(median 15.0 years vs. median 16.0 years) were observed
between RA patients positive or negative for the CCR5 d32
deletion.
The study cohort analyzed has previously been investigated for
an association between a polymorphism in the DNASE2 gene,
which codes for an exonuclease required for DNA degradation
in lysosomes. Analysis of genotyping results for the CCR5d32
deletion in conjunction with the presence of the homozygous
RA associated SNP in the DNASE2 gene revealed an additive
effect of the two genetic markers. In patients homozygous for
the RA associated DNASE2 -1066 G allele, a further
decrease of the frequency of CCR5d32 was statistically sig-
nificant (10.3% vs. 19.8%, P = 0.004 using McNemar's test).
Table 2
CCR5 d32 case-control analysis
Controls
(n = 459)
RA
(n = 503)
P values
Allele wt 795 (86.6) 905 (90.0)
d32 123 (13.4) 101 (10.0) 0.0262
genotype wt/wt 343 (74.7) 409 (81.3)
wt/d32 109 (23.7) 87 (17.3)
d32/d32 7 (1.5) 7 (1.4) 0.0437
wt/d32+
d32/d32
116 (25.3) 94 (18.7) 0.0168
Values are the absolute numbers of genotypes or alleles with 
frequencies in percent given in parentheses. P values were 
calculated using chi-squares test with 2 × 2 contigency tables 
(alleles) or 2 × 3 contigency tables (genotypes) for comparison of 
frequencies of the indicated markers in the patients compared with 
the controls.
RA = rheumatoid arthritis; wt = wild type.Arthritis Research & Therapy    Vol 11 No 3    Rossol et al.
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Accordingly, the simultaneous presence of homozygosity for
DNASE2 -1066 G and of the CCR5 wild type allele was asso-
ciated with a further increase in RA susceptibility (OR = 2.28,
P = 0.0051).
Analysis of radiographic findings revealed an association of a
milder disease course with the CCR5 d32 deletion (Table 3).
In patients without radiographic evidence of bone erosions,
the CCR5d32 deletion was present more frequently than in
patients with erosive disease (29.6% versus 14.5%, P  =
0.0047). Accordingly, the increased frequency of the wild type
allele in the patient group with erosions resulted in an OR of
2.47 for erosive joint disease. The disease duration at the time
of radiographic analysis did not differ between CCR5d32-
positive patients with joint erosions and those with non-erosive
disease (median 15 years vs. median 13 years, not statistically
significant). Furthermore, no significant differences in the
patients' age at onset of the disease were found between the
two groups (median 56 years vs. median 46 years, not statis-
tically significant).
In order to assess the relation between the CCR5d32 deletion
and disease activity, all documented CRP values from the
patients followed in the Department of Rheumatology at Leip-
zig University were determined (median 21 values per patient
over the total disease duration). Patients carrying the deletion
had significantly lower mean CRP values compared with
patients homozygous for the wild type (median 8.85 vs.
median 14.1, P = 0.0041, Figure 1).
To further analyze the influence of the CCR5 d32 deletion on
the clinical course of the disease, the occurrence of the follow-
ing symptoms of extra-articular disease was investigated:
presence of nodular RA, major organ vasculitis, serositis, pul-
monary fibrosis, or Raynaud's syndrome. The frequency of
CCR5 d32 was significantly lower in patients with extra-artic-
ular manifestations compared with those without extra-articu-
lar disease (13.2% versus 22.8%, P = 0.0374). However, no
significant association with any individual symptom was dis-
cernible, (data not shown).
Stratification of patients for the presence or absence of RF
IgM, RF IgA, anti-CCP antibodies, or ANAs did not reveal a
significant influence of those parameters on the CCR5 d32
genotype distributions in the patient subgroups (data not
shown).
Two independent RA cohorts were chosen for the replication
study on the association of CCR5 d32 with the inflammatory
response, joint erosion, and DNASE2. In the early RA cohort,
CRP levels at the onset of disease were determined. Patients
carrying the deletion had significantly lower CRP values at dis-
ease onset compared with patients homozygous for the wild
type (median 8.0 vs. median 12.0, P = 0.028, n = 251).
For both cohorts, radiographic data were available, which had
been scored according to the Ratingen score. In the early RA
cohort, no significant difference in the Ratingen score
between patients carrying the deletion and patients with the
wild type CCR5 after two years of disease onset was
observed (median 2.0 vs. median 4.0, P = 0.5337, n = 141).
In the other cohort, radiographic data were available from at
least two time points, one taken during the first 10 years of dis-
ease duration and one taken after more than 10 years of dis-
ease duration. At both time points, a lower Ratingen score was
observed in patients with CCR5 d32 in comparison to patients
carrying the wild type CCR5 (<10 years: median 7.0 vs.
median 10.0, P = 0.0324, n = 158; = 10 years: median 14.0
vs. 26.0, P = 0.0219, n = 118).
Table 3
Comparison of genotype frequencies for CCR5 d32 in patients with rheumatoid arthritis stratified for erosive disease and 
extraarticular manifestations
Genotype P value
wt/wt wt/d32+d32/d32
Erosive disease
Yes (n = 296) 253 (85.5) 43 (14.5)
No (n = 71) 50 (70.4) 21 (29.6) 0.0047
Extraarticular manifestions
Yes (n = 144) 125 (86.8) 19 (13.2)
No (n = 184) 142 (77.2) 42 (22.8) 0.0374
Values are the absolute numbers of genotypes with frequencies in percent given in parentheses. P values were calculated using chi-squared test 
with 2 × 2 contigency tables for comparison of frequencies of the indicated marker in the rheumatoid arthritis patient subgroups. Data for erosive 
disease status and the presence of extraarticular manifestions was not available for 136 and 175 patients, respectively.
wt = wild type.Available online http://arthritis-research.com/content/11/3/R91
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A total of 470 patients of both additional RA cohorts were gen-
otyped for the DNASE2 -1066 SNP. In patients homozygous
for the RA associated DNASE2 -1066 G allele, a significant
lower frequency of CCR5 d32 was observed (12.5% vs.
22.3%, P < 0.0001 using McNemar's test).
Discussion
We report for the first time a significant influence of the pres-
ence of the CCR5 d32 deletion on the inflammatory response
in RA, the occurrence of extra-articular manifestations of RA,
and on the presence of erosive disease.
Published results of the initial disease association studies are
somewhat conflicting. The negative association of the CCR5
d32 deletion with RA susceptibility was observed exclusively
for homozygous carriers in one study [5], and was limited to
seropositive or more severe disease in other studies [19,20].
More recently, a pooled analysis of all published case-control
studies until 2006 [7], and the combination of this meta-anal-
ysis with at least one subsequent study [8] supported the
notion of a significant negative association of the CCR5 d32
deletion with RA. The data presented here provide further evi-
dence for such a protective effect.
Ethnic effects are likely to account at last in part for some of
the discrepancies. The frequency of carriers of the CCR5 d32
deletion varies widely between different ethnic groups [5]. The
d32 deletion is absent in native Africans, American Indians, or
East Indians, and is likely to have arisen by mutation in north-
east Europe, and possibly even from northern Germany [29],
which might explain the comparatively high frequency of the
allele in our Saxonian, German population. In the initial study
cohort, heterozygotes and homozygotes combined account
for 25% of healthy controls, which exceeds the frequencies in
control populations in many published studies. Therefore, the
ethnic characteristic of the German population might contrib-
ute to the significant associations observed in the study,
because the detection of potential influences of genetic
parameters on disease course and susceptibility is facilitated
by a higher population frequency.
In addition to the protective effect on disease susceptibility,
the CCR5 d32 deletion has previously been reported to influ-
ence clinical disease parameters. Patients carrying the dele-
tion allele were preferentially negative for RF IgM, had less
frequently swollen joints, and had shorter morning stiffness
compared with those patients homozygous for the normal
allele [19].
In contrast, a published study in Mexican patients with RA
found no difference in allele distribution between RA patients
and controls or between treatment refractory and non-refrac-
tory patient groups. An ethnic characteristic of this study was
the rather low frequency of the CCR5d32 deletion in all ana-
lyzed ethnic groups and in the RA patients (<3% of all individ-
uals), which might impede detection of genetic influences with
statistical significance [30]. A study by Pokorny and col-
leagues also detected no influence of the CCR5d32 deletion
on disease severity or outcome in the prospective early RA
cohort [6]. However, this analysis was performed in an early
RA cohort of only 92 patients who were followed prospectively
for two years, and significant influences on erosive joint
destructions might have been missed due to the small patient
number.
In contrast to those earlier reports, we saw no preferential
association of the CCR5 d32 deletion with RF seronegative or
anti-CCP-negative disease, although there was a trend, which
did not reach statistical significance. The strongest influences
of the genetic marker observed in our cohort were a significant
association with non-erosive joint disease and a decreased
inflammatory response in carriers of the deletion. In addition,
the partial replication of those clinical associations in two addi-
tional study cohorts indicates that the influence of the deletion
on the clinical disease course is a relevant and potentially clin-
ically meaningful observation.
We recently reported the association of polymorphisms in the
DNASE2 gene, which codes for an exonuclease required for
DNA degradation in lysosomes, with increased susceptibility
for RA in the same cohort [21]. In addition, DNASE2 knock-out
mice spontaneously develop chronic polyarthritis resembling
human RA [31]. Here, we report a lower frequency of the
CCR5 d32 deletion in RA patients homozygous for the RA
associated SNP in the DNASE2 gene and therefore a further
increase in RA susceptibility in the simultaneous presence of
Figure 1
Median CRP levels are lower in patients with rheumatoid arthritis carry- ing CCR5 d32 Median CRP levels are lower in patients with rheumatoid arthritis carry-
ing CCR5 d32. Box plot depicts median and interquartile range of the 
averaged C-reactive protein (CRP) values that were calculated for indi-
vidual patients from all measurements available for retrospective analy-
sis.Arthritis Research & Therapy    Vol 11 No 3    Rossol et al.
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homozygosity for DNASE2 -1066 G and of the CCR5 wild
type allele.
As DNASE2 and CCR5 are both expressed in monocytes and
macrophages, one might speculate that increased levels of
DNA that have escaped degradation in macrophages due to a
lower expression rate of the enzyme might lead to production
of chemokines which in turn bind to CCR5 further activating
these cells and surrounding cells, such as CD4+ T cells. The
expression of non-functional CCR5 in humans carrying the
CCR5 d32 deletion would have a protective effect by
decreasing the activation of CCR5 and therefore diminishing
migration of these cells into the synovial membrane.
The relevance of signaling of CCR5 in destructive arthritis has
been demonstrated in primates by the inhibition of collagen-
induced arthritis in rhesus monkeys by a CCR5 antagonist
[32]. The precise role of CCR5 signaling in the pathogenesis
of human RA is unclear, but ligand binding to the receptor has
been shown to down-modulate its expression [2], which also
appears to be in part genetically determined by the presence
of CCR5 d32 [33]. Expression levels of CCR5, in turn, have
been reported to be increased in active and decreased in less
active disease, and a good clinical response to anti-TNFα
treatment might be predicted by high percentages of CCR5
expressing T cells [34]. It could be hypothesized, therefore,
that a genetically determined decrease in CCR5 expression is
the underlying reason for the observed association with non-
erosive and less severe disease.
Conclusions
In the study presented here, the frequency of a genetic poly-
morphism resulting in a deletion of the CCR5 gene was ana-
lyzed in a large cohort of patients with RA and in healthy
controls. The protective effect of the deletion known from
other studies could be confirmed. In addition, a significant sta-
tistical influence of the polymorphism on the clinical course of
the autoimmune disease was observed. Carriers of the dele-
tion were protected from joint erosions, were less frequently
affected by extra-articular manifestations of the disease, and
had lower cumulative CRP levels. This association indicates
clinical usefulness of the deletion as a prognostic diagnostic
marker as well as a likely pathogenetic role for CCR5.
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